Generex Awarded New Patent in Morocco
Generex Biotechnology Corporation announced that it has received a new patent in Morocco. The Moroccan Industrial and Commercial Property Office granted the Company its first Moroccan patent, titled "Orally Absorbed Pharmaceutical Formulation and Method of Administration." The patent contains claims to pharmaceutical formulations effective to deliver a pharmaceutical agent across oral membranes as well as device and method claims.
"While our regulatory scope in the Middle East region expands, the granting of this application in Morocco is a timely one," said Rose Perri, the Company's Chief Operating Officer. “We look forward to other patent grants that will augment the value of our increasing intellectual property portfolio.”
Generex currently holds an aggregate of 143 patents worldwide (21 of which are United States patents) and has an aggregate of 119 patent applications pending in various jurisdictions.
Other news from the department research and development
These products might interest you

Hydrosart® Ultrafilter by Sartorius
Efficient ultrafiltration for biotech and pharma
Maximum flow rates and minimum protein loss with Hydrosart® membranes

Hydrosart® Microfilter by Sartorius
Hydrophilic microfilters for bioprocesses
Minimal protein adsorption and high flow rates

Sartopore® Platinum by Sartorius
Efficient filtration with minimal protein adsorption
Reduces rinsing volume by 95 % and offers 1 m² filtration area per 10"

Polyethersulfone Ultrafilter by Sartorius
Reliable filtration with PESU membranes
Perfect for biotechnology and pharmaceuticals, withstands sterilisation and high temperatures

Polyethersulfone Microfilter by Sartorius
Biotechnological filtration made easy
Highly stable 0.1 µm PESU membranes for maximum efficiency

Sartobind® Rapid A by Sartorius
Efficient chromatography with disposable membranes
Increase productivity and reduce costs with fast cycle times

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Images of antibodies working together against malaria

Chemie.DE Information Service's 10th Anniversary: an Online Success Story
Evocatal GmbH Closes New Financing Round

Eppendorf opens new site in Singapore - Targeted strengthening of customer focus with high-tech laboratory for pipette calibration and extensive range of high-quality laboratory services

Evotec enters partnership with Vienna start-up - Quantro exploits innovative functional-genetic and transcriptomic technologies to address “undruggable” targets

BluCon Biotech and LG Chem enter into unique investment agreement - BluCon Biotech's technology has the potential to be a disruptive game changer in the world's plastics market

Antibiotic ribosomal compounds deciphered - Combating multidrug-resistant bacteria through high-resolution structural imaging
Illumina and Oxford Nanopore Enter into Broad Commercialization Agreement - Single-Molecule DNA Sequencing System Promises Dramatic Improvement in Cost, Speed, Versatility, and Simplicity of Sequencing
CT Atlantic AG Announces Appointment of Michael Höcker to CEO - Cara Lerner joins CT Atlantic as COO
